| Host: |
HEK293 |
| Note: |
STRICTLY FOR FURTHER RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS. |
| Short Description: |
Recombinant-Human TGF-beta RII/TGFBR2-C-mFc-Avi protein was developed from hek293 and has a target region of C-mFc-Avi. For use in research applications. |
| Conjugation: |
Biotin |
| Formulation: |
Lyophilised from 0.2 µm filtered PBS solution pH7.4. |
| Dilution Range: |
Upon receipt centrifuge vial to ensure maximal product extraction, recommended: 20sec, 5K RPM |
| Storage Instruction: |
The lyophilized protein is stable for at least 1 year from date of receipt at-20°C. |
| Endotoxin: |
Endotoxin content was assayed using a LAL gel clot method. Endotoxin level was found to be less than 0.1 ng/µg (1EU/µg). |
| Gene Symbol: |
TGFBR2 |
| Gene ID: |
7048 |
| Uniprot ID: |
TGFR2_HUMAN |
| Immunogen Region: |
Ile24-Asp159 |
| Immunogen: |
DNA sequence encoding Human TGF-beta RII/TGFBR2 including a C-mFc-Avi tag was expressed in HEK293 Cells. The recombinant protein was then biotinylated site specific using the AVItag biotinylation technology. |
| Function | Transmembrane serine/threonine kinase forming with the TGF-beta type I serine/threonine kinase receptor, TGFBR1, the non-promiscuous receptor for the TGF-beta cytokines TGFB1, TGFB2 and TGFB3. Transduces the TGFB1, TGFB2 and TGFB3 signal from the cell surface to the cytoplasm and thus regulates a plethora of physiological and pathological processes including cell cycle arrest in epithelial and hematopoietic cells, control of mesenchymal cell proliferation and differentiation, wound healing, extracellular matrix production, immunosuppression and carcinogenesis. The formation of the receptor complex composed of 2 TGFBR1 and 2 TGFBR2 molecules symmetrically bound to the cytokine dimer results in the phosphorylation and activation of TGFBR1 by the constitutively active TGFBR2. Activated TGFBR1 phosphorylates SMAD2 which dissociates from the receptor and interacts with SMAD4. The SMAD2-SMAD4 complex is subsequently translocated to the nucleus where it modulates the transcription of the TGF-beta-regulated genes. This constitutes the canonical SMAD-dependent TGF-beta signaling cascade. Also involved in non-canonical, SMAD-independent TGF-beta signaling pathways. Isoform 1: Has transforming growth factor beta-activated receptor activity. Isoform 2: Has transforming growth factor beta-activated receptor activity. Isoform 3: Binds TGFB1, TGFB2 and TGFB3 in the picomolar affinity range without the participation of additional receptors. Blocks activation of SMAD2 and SMAD3 by TGFB1. |
| Protein Name | Tgf-Beta Receptor Type-2Tgfr-2Tgf-Beta Type Ii ReceptorTransforming Growth Factor-Beta Receptor Type IiTgf-Beta Receptor Type IiTbetar-Ii |
| Database Links | Reactome: R-HSA-2173788Reactome: R-HSA-2173789Reactome: R-HSA-2173791Reactome: R-HSA-3304356Reactome: R-HSA-3642279Reactome: R-HSA-3645790Reactome: R-HSA-3656532Reactome: R-HSA-3656535Reactome: R-HSA-5689603Reactome: R-HSA-9839389 |
| Cellular Localisation | Cell MembraneSingle-Pass Type I Membrane ProteinMembrane RaftIsoform 3: Secreted |
| Alternative Protein Names | Tgf-Beta Receptor Type-2 proteinTgfr-2 proteinTgf-Beta Type Ii Receptor proteinTransforming Growth Factor-Beta Receptor Type Ii proteinTgf-Beta Receptor Type Ii proteinTbetar-Ii proteinTGFBR2 protein |
Information sourced from Uniprot.org
12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance
